Skip to main content

Table 1 Pathologic and immunohistochemical characteristics that were significantly different in BRCA1-associated breast cancers with and without loss of wt BRCA1

From: Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers

Variables Loss of wt BRCA1 No loss of wt BRCA1 P-value
  N(%) N(%)  
Sample Size 65 12  
Histology    
Ductal* 59 (90.8) 8 (66.7) 0.043
Ductal/Lobular 4 (6.1) 3 (25)  
Other 2 (3.1) 1 (8.3)  
Mitoses/10 high power field    
   0 to 5* 10 (15.4) 8 (66.7) < 0.001*
   6 to 10 14 (21.5) 0  
   > 10 41 (63.1) 4 (33.3)  
Grade    
   1 (3 to 5 points) 5 (7.7) 5 (41.7)  
   2 (6 to 7 points) 7 (10.8) 3 (25)  
   3 (8 to 9 points)* 53 (81.5) 4 (33.3) 0.001*
CK5/6 58 11  
Positive 29 (50) 0 (0) < 0.001*
Negative 29 (50) 11 (100)  
CK14 58 9 0.023
Positive 23 (39.7) 0  
Negative 35 (60.3) 9 (100)  
CK5/6 or CK14 60 12 < 0.001*
Positive 35 (58.3) 0 ((0)  
Negative 25 (41.7) 12 (100)  
CK5/6 and/or CK14 and/or EGFR 61 12 0.023
Positive 39 (63.9) 3 (25)  
Negative 22 (36.1) 9 (75)  
  1. Abbreviations: ER, estrogen receptor; CK, cytokeratin; EGFR, epidermal growth factor receptor.
  2. Loss of wt: cancers with LOH with loss of wt BRCA1 allele.
  3. No loss of wt: includes cancers with no LOH and LOHmut.
  4. *P-value retained significance with Bonferroni adjustment for multiple comparisons.
  5. Percentages calculated by column.